Ticker

VIRO.CO

ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting. The company' products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood. The company was founded in 2000 and is headquartered in Birkerød, Denmark.